Division of Cardiology Department of Medicine University of California, San Francisco CA.
Division of Cardiology Department of Medicine San Francisco Veterans Affairs Health Care System San Francisco CA.
J Am Heart Assoc. 2020 Aug 4;9(15):e016463. doi: 10.1161/JAHA.120.016463. Epub 2020 Jul 22.
Background Chronic kidney disease (CKD) confers increased cardiovascular risk, not fully explained by traditional factors. Proteins regulate biological processes and inform the risk of diseases. Thus, in 938 patients with stable coronary heart disease from the Heart and Soul cohort, we quantified 1054 plasma proteins using modified aptamers (SOMAscan) to: (1) discern how reduced glomerular filtration influences the circulating proteome, (2) learn of the importance of kidney function to the prognostic information contained in recently identified protein cardiovascular risk biomarkers, and (3) identify novel and even unique cardiovascular risk biomarkers among individuals with CKD. Methods and Results Plasma protein levels were correlated to estimated glomerular filtration rate (eGFR) using Spearman-rank correlation coefficients. Cox proportional hazard models were used to estimate the association between individual protein levels and the risk of the cardiovascular outcome (first among myocardial infarction, stroke, heart failure hospitalization, or mortality). Seven hundred and nine (67.3%) plasma proteins correlated with eGFR at <0.05 (ρ 0.06-0.74); 218 (20.7%) proteins correlated with eGFR moderately or strongly (ρ 0.2-0.74). Among the previously identified 196 protein cardiovascular biomarkers, just 87 remained prognostic after correction for eGFR. Among patients with CKD (eGFR <60 mL/min per 1.73 m), we identified 21 protein cardiovascular risk biomarkers of which 8 are unique to CKD. Conclusions CKD broadly alters the composition of the circulating proteome. We describe protein biomarkers capable of predicting cardiovascular risk independently of glomerular filtration, and those that are prognostic of cardiovascular risk specifically in patients with CKD and even unique to patients with CKD.
慢性肾脏病(CKD)会增加心血管风险,而这不能完全用传统因素来解释。蛋白质调节着生物过程,并提示着疾病的风险。因此,在 Heart and Soul 队列中,我们对 938 例稳定型冠心病患者进行了 1054 种血浆蛋白的定量分析,这些蛋白是利用改良适体(SOMAscan)来检测的:(1)分辨肾小球滤过率降低如何影响循环蛋白质组;(2)了解肾功能对最近确定的蛋白质心血管风险生物标志物中包含的预后信息的重要性;(3)在 CKD 患者中确定新的甚至是独特的心血管风险生物标志物。
使用 Spearman 等级相关系数将血浆蛋白水平与估计肾小球滤过率(eGFR)相关联。Cox 比例风险模型用于估计个体蛋白水平与心血管结局风险(首次发生心肌梗死、中风、心力衰竭住院或死亡)之间的关联。709 种(67.3%)血浆蛋白与 eGFR 相关(ρ 0.06-0.74),218 种(20.7%)蛋白与 eGFR 中度或强烈相关(ρ 0.2-0.74)。在之前确定的 196 种蛋白质心血管生物标志物中,只有 87 种在纠正 eGFR 后仍具有预后价值。在 CKD 患者(eGFR <60 mL/min/1.73 m)中,我们确定了 21 种蛋白质心血管风险生物标志物,其中 8 种是 CKD 特有的。
CKD 广泛改变了循环蛋白质组的组成。我们描述了能够独立于肾小球滤过预测心血管风险的蛋白质生物标志物,以及那些在 CKD 患者中具有预后价值的生物标志物,甚至是 CKD 患者特有的生物标志物。